02196 PE Ratio & Valuation, Is 02196 Overvalued

Historical Valuation

FOSUN PHARMA (02196) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 14.56. The fair price of FOSUN PHARMA (02196) is between NaN to NaN according to relative valuation method.

Relative Value

Fair Zone

NaN-NaN

Current Price：20.10

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is FOSUN PHARMA (02196) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

FOSUN PHARMA (02196) has a current Price-to-Book (P/B) ratio of 1.01. Compared to its 3-year average P/B ratio of 1.43, the current P/B ratio is approximately -29.18% higher. Relative to its 5-year average P/B ratio of 2.14, the current P/B ratio is about -52.74% higher. FOSUN PHARMA (02196) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.31%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -1.37%, the current FCF yield is about -100.00% lower.

Performance Decomposition

AI Analysis

Market capitalization of 02196 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 02196 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 02196 currently overvalued or undervalued?

What is FOSUN PHARMA (02196) fair value?

02196's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of FOSUN PHARMA (02196) is between NaN to NaN according to relative valuation method.

How does 02196's valuation metrics compare to the industry average?

The average P/S ratio for 02196's competitors is 0.00, providing a benchmark for relative valuation. FOSUN PHARMA Corp (02196) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for FOSUN PHARMA (02196) as of Apr 21 2026?

As of Apr 21 2026, FOSUN PHARMA (02196) has a P/B ratio of 1.01. This indicates that the market values 02196 at 1.01 times its book value.

What is the current FCF Yield for FOSUN PHARMA (02196) as of Apr 21 2026?

As of Apr 21 2026, FOSUN PHARMA (02196) has a FCF Yield of 0.00%. This means that for every dollar of FOSUN PHARMA's market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for FOSUN PHARMA (02196) as of Apr 21 2026?

As of Apr 21 2026, FOSUN PHARMA (02196) has a Forward P/E ratio of -174.91. This means the market is willing to pay $-174.91 for every dollar of FOSUN PHARMA's expected earnings over the next 12 months.

What is the current Forward P/S ratio for FOSUN PHARMA (02196) as of Apr 21 2026?

As of Apr 21 2026, FOSUN PHARMA (02196) has a Forward P/S ratio of 0.00. This means the market is valuing 02196 at $0.00 for every dollar of expected revenue over the next 12 months.

02196 Valuation